The European Medicines Agency (EMA) has published a Questions and Answers document on the implementation of European Pharmacopoeia (Ph. Eur.) Medicinal Product Monographs (MPM), aiming to clarify regulatory expectations for marketing authorisation holders and applicants. The document, released on 5 May 2026, addresses practical aspects of transitioning from substance-based to product-specific monographs, which will affect how medicinal products are described in dossiers and labelling.
The Q&A document, issued by EMA's Quality Office, provides guidance on the scope and application of MPMs, which are being introduced to standardise product descriptions across the EU. It covers topics such as the definition of a medicinal product monograph, the relationship with existing substance monographs, and the impact on ongoing and future marketing authorisation applications. The document is non-binding but represents the agency's current thinking.
Policy orientations and trade-offs
The guidance reflects a shift towards more detailed product-specific standards, which may improve consistency and quality but could increase regulatory burden for manufacturers. The Q&A attempts to balance harmonisation with flexibility, allowing for some adaptation to product-specific characteristics.
Impact on stakeholders
- Pharmaceutical industry: Companies will need to update their dossiers to align with MPM requirements, potentially increasing costs for re-submissions and labelling changes. However, clearer standards may reduce long-term uncertainty.
- National competent authorities: The guidance supports uniform interpretation across member states, facilitating mutual recognition and decentralised procedures.
- Patients: Standardised product descriptions may improve traceability and safety, though the direct impact is indirect.
- EMA itself: The agency will need to manage increased queries and review workload during the transition.
Expected institutional follow-up
EMA plans to update the Q&A periodically based on stakeholder feedback and implementation experience. The European Pharmacopoeia Commission will continue to develop new MPMs, and EMA may issue further guidance on specific product categories. The document is available on EMA's website for public consultation.